1290634-39-7

Upstream product

• 49834-22-2 3-bromo-N-methylbenzamide 
• 75-16-1 methylmagnesium bromide 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 74-89-5 methylamine 

Downstream Products

• 1290634-40-0 7-bromo-3-(3-chlorophenyl)isoquinolin-1(2H)-one 
• 1290634-41-1 7-bromo-3-(3-chlorophenyl)-2-methylisoquinolin-1(2H)-one 
• 1290636-49-5 7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-3-(3-chlorophenyl)-2-methylisoquinolin-1(2H)-one 
• 1421921-85-8 5-{2-[4-({(E)-[ethyl(methyl)amino]methylidene}amino)-2,5-dimethylbenzyl]-1,3-thiazol-4-yl}-N,2-dimethylbenzamide 
• 1421923-02-5 5-(bromoacetyl)-N,2-dimethylbenzamide 
• 1421923-01-4 5-acetyl-N,2-dimethylbenzamide 
• 1421923-00-3 C₁₃H₁₇NO₂ 

Relevant academic research and scientific papers

Manganese-catalyzed directed methylation of C(sp2)-H bonds at 25 °C with high catalytic turnover

We report here a manganese-catalyzed C-H methylation reaction of considerable substrate scope, using MeMgBr, a catalytic amount of MnCl2· 2LiCl, and an organic dihalide oxidant. The reaction features ambient temperature, low catalyst loading, typically 1%, high catalytic turnover reaching 5.9 × 103, and no need for an extraneous ligand and illustrates a unique catalytic use of simple manganese salts for C-H activation, which so far has relied on catalysis by manganese carbonyls.

CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR

The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by nicotinic acetylcholine receptors, such as schizophrenia and Alzheimer's disease.